



IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/566,625
APPLICANTS : Klaus, et al.
FILING DATE : 30 January 2006
GROUP ART UNIT : Unassigned
EXAMINER : Unassigned
DOCKET NO. : FP0617 US
TITLE : INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS
GAMMA GLOBIN INDUCERS

Commissioner for Patents
PO Box 1451
Alexandria VA 22313-1450

TRANSMITTAL

The following items accompany this Transmittal:

1. Return Receipt Postcard.
2. Supplemental Information Disclosure Statement (2 pages)(in duplicate)
3. PTO/SB/08A (5 pages)
4. References (44)

Applicants claim small entity status under 37 C.F.R. 1.27.

Please call Applicants' representative at 650.866.7265 with any questions regarding this communication or the above-referenced application. The Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811, referencing Docket No. FP00617 US. This form is enclosed in duplicate.

Respectfully submitted,

Date: 12 April 2006

By:

Christopher Turner, Ph.D.
Reg. No. 45,167

FIBROGEN, INC.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650.866.7200
Direct: 650.866.7265
Facsimile: 650.866.7292
cturner@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 13 April 2006.

Name: Michael Moores

Signature:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/566,625
APPLICANTS : Klaus, et al.
FILING DATE : 30 January 2006
GROUP ART UNIT : Unassigned
EXAMINER : Unassigned
DOCKET NO. : FP0617 US
TITLE : INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS
GAMMA GLOBIN INDUCERS

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97(b)

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "Information Disclosure Statement By Applicant" (Form PTO/SB/08A). Applicants reserve the right to antedate any reference in accordance with standard procedure. In accordance with 37 CFR 1.98(a)(2)(ii), copies of any issued U.S. patents or published U.S. patent applications are not enclosed.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on /3 April 2006.

Name: Michael Moores

Signature: _____


attached to the markings. Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Form PTO/SB/08A be returned to Applicants.

If there are any questions regarding this communication, please call the undersigned at 650-866-7265.

Applicants believe that no fee is due in this communication since it is being filed within three months of the filing date, or prior to the receipt of the first office action on the merits. If, however, the Commissioner determines that a fee is due, authorization is hereby given to charge the total of any such fee to Deposit Account No. 50-0811, referencing Docket No. FP0617 US. This form is enclosed in duplicate.

Respectfully submitted,

Date: 12 April 2006


Christopher Turner, Ph.D.
Reg. No. 45,167

FIBROGEN, INC.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650.866.7200
Direct: 650.866.7265
Facsimile: 650.866.7292
cturner@fibrogen.com

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	FP0617 US

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 4,822,821	04-18-1989	Perrine, Susan	
	AB	US- 5,700,640-A	12-23-1997	Voss, et al.	
	AC	US- 6,011,000-A	01-04-2000	Perrine, et al.	
	AD	US- 6,218,122-B1	04-17-2001	Friend, et al.	
	AE	US- 6,231,880-B1	05-15-2001	Perrine, Susan	
	AF	US- 6,331,564-B1	12-18-2001	Brugnara, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	BA	WO - 93/18761 - A1	09-30-1993	Child Hosp Med Ctr Nor CA		
	BB	WO - 96/08242 - A3	03-21-1996	Children's Med Ctr Corp		
	BC	WO - 99/24034 - A1	05-20-1999	Children's Med Ctr Corp		
	BD	WO - 03/049686 - A2	06-19-2003	FibroGen, Inc.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ADDAE, S., et al., "Survival of Patients With Sickle Cell Anemia Living at High Altitude," South Med J, 1990, Vol. 83, No. 4, p. 487.	
	CB	AL-KHATTI, A., et al., "Erythropoietin Stimulates F-Reticulocyte Formation in Sickle Cell Anemia," Trans. Assoc. Am. Physicians, 1988, Vol. 101, pp. 54-61.	
	CC	BARD, Harry, et al., "Hypoxemia and Increased Fetal Hemoglobin Synthesis," J Pediatrics, 1994, Vol. 124, No. 6, pp. 941-943.	
	CD	BICKEL, Martin, et al., "Selective Inhibition of Hepatic Collagen Accumulation in Experimental Liver Fibrosis in Rats by a New Prolyl 4-Hydroxylase Inhibitor," Hepatology, 1998, Vol. 28, No. 2, pp. 404-411.	
	CE	BLAU, Anthony, et al., "Fetal Hemoglobin Induction With Butyric Acid: Efficacy and Toxicity," Blood, 1993, Vol. 81, No. 2, pp. 529-537.	
	CF	CHARACHE, Samuel, et al., "Hydroxyurea-Induced Augmentation of Fetal Hemoglobin Production in Patients With Sickle Cell Anemia," Blood, 1987, Vol. 69, No. 1, pp. 109-116.	
	CG	CHARACHE, Samuel, et al., "Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia," N Engl J Med, 1995, Vol. 332, No. 20, pp. 1317-1322.	
	CH	COKIC, Vladan P., et al., "Hydroxyurea Induces Fetal Hemoglobin by the Nitric Oxide-Dependent Activation of Soluble Guanylyl Cyclase," J Clin Invest, 2003, Vol. 111, No. 2, pp. 231-239.	
	CI	CONSTANTOULAKIS, P., et al., "On the Induction of Fetal Hemoglobin by Butyrates: In Vivo and In Vitro Studies With Sodium Butyrate and Comparison of Combination Treatments With 5-AzaC and AraC," Blood, 1989, Vol. 74, No. 6, pp. 1963-1971	
	CJ	DESIMONE, Joseph, et al., "Stimulation of Fetal Hemoglobin Synthesis in Baboons by Hemolysis and Hypoxia," Proc. Natl. Acad. Sci. USA, 1978, Vol. 75, No. 6, pp. 2937-2940.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	DESIMONE, Joseph, et al., "Maintenance of Fetal Hemoglobin (HbF) Elevations in the Baboon by Prolonged Erythropoietic Stress," Blood, 1982, Vol. 60, No. 2, pp. 519-523.	
	CL	DESIMONE, Joseph, et al., "Maintenance of Elevated Fetal Hemoglobin Levels by Decitabine During Dose Interval Treatment of Sickle Cell Anemia," Blood, 2002, Vol. 99, No. 11, pp. 3905-3908.	
	CM	FIBACH, Eitan, et al., "Enhanced Fetal Hemoglobin Production by Phenylacetate and 4-Phenylbutyrate in Erythroid Precursors Derived From Normal Donors and Patients With Sickle Cell Anemia and β -Thalassemia," Blood, 1993, Vol. 82, No. 7, pp. 2203-2209.	
	CN	FIBACH, Eitan, et al., "Mithramycin Induces Fetal Hemoglobin Production in Normal and Thalassemic Human Erythroid Precursor Cells," Blood, 2003, Vol. 102, No. 4, pp. 1276-1281.	
	CO	FRANKLIN, Trevor J., et al., "Approaches to the Design of Anti-Fibrotic Drugs," Biochem Soc Trans, 1991, Vol. 19, pp. 812-815.	
	CP	FRANKLIN, Trevor J., et al., "Inhibition of Prolyl 4-Hydroxylase In Vitro and In Vivo by Members of a Novel Series of Phenanthrolinones," Biochem J, 2001, Vol. 353, pp. 333-338.	
	CQ	FRIEDMAN, Lisa, et al., "Prolyl 4-Hydroxylase is Required for Viability and Morphogenesis in Caenorhabditis elegans," PNAS, 2000, Vol. 97, No. 9, pp. 4736-4741.	
	CR	GABBIANELLI, Marco, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Reactivates Fetal Hemoglobin Synthesis in Erythroblast Clones From Normal Adults," Blood, 1989, Vol. 74, No. 8, pp. 2657-2667.	
	CS	GABBIANELLI, Marco, et al., "Hemoglobin Switching in Unicellular Erythroid Culture of Sibling Erythroid Burst-Forming Units: Kit Ligand Induces a Dose-Dependent Fetal Hemoglobin Reactivation Potentiated by Sodium Butyrate," Blood, 2000, Vol. 95, No. 11, pp. 3555-3561.	
	CT	JIANG, Jinjie, et al., "In Vivo Production of Nitric Oxide in Rats After Administration of Hydroxyurea," Mol Pharmacol, 1997, Vol. 52, pp. 1081-1086.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	5	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	KIVIRIKKO, Kari I., et al., "Prolyl 4- Hydroxylases and Their Protein Disulfide Isomerase Subunit," Matrix Biol, 1997, Vol. 16, pp. 357-368.	
	CV	LETVIN, Norman L., et al., "Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by Hydroxyurea," N Engl J Med, 1984, Vol. 310, No. 14, pp. 869-873.	
	CW	LEY, Timothy J., et al., "Induction of Hemoglobin F Synthesis in Patients With β - Thalassemia," Annu Rev Med, 1985, Vol. 36, pp. 485-498.	
	CX	LEY, Timothy J., et al., "5-Azacytidine Selectively Increases γ -globin Synthesis in a Patient With β + Thalassemia," N Engl J Med, 1982, Vol. 307, No. 24, pp. 1469-1475.	
	CY	MAJAMAA, Kari, et al., "The 2-Oxoglutarate Binding Site of Prolyl 4-Hydroxylase," Eur J Biochem, 1984, Vol. 138, pp. 239-245.	
	CZ	MAJAMAA, Kari, et al., "Differences Between Collagen Hydroxylases and 2-Oxoglutarate Dehydrogenase in Their Inhibition by Structural Analogues of 2-Oxyglutarate," Biochem J, 1985, Vol. 229, pp. 127-133.	
	CAA	MIGLIACCIO, Anna R., et al., "Influence of Recombinant Hematopoietin and of Fetal Bovine Serum on the Globin Synthetic Pattern of Human BFUe," Blood, 1990, Vol. 76, No. 6, pp. 1150-1157.	
	CBB	MILLER, Barbara A., et al., "High Fetal Hemoglobin Production in Sickle Cell Anemia in the Eastern Province of Saudi Arabia is Genetically Determined," Blood, 1986, Vol. 67, No. 5, pp. 1404-1410.	
	CCC	MILLER, Barbara A., et al., "Influence of Steel Factor on Hemoglobin Synthesis in Sickle Cell Disease," Blood, 1992, Vol. 79, No. 7, pp. 1861-1868.	
	CDD	PARTINGTON, G.A., et al., "Human Globin Gene Transcription in Injected Xenopus Oocytes: Enhancement by Sodium Butyrate," EMBO J, 1984, Vol. 3, No. 12, pp. 2787-2792.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	5	of	5	Application Number	10/566,625
				Filing Date	30 January 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CEE	PEMBREY, M.E., et al., "Fetal Haemoglobin Production and the Sickle Gene in the Oases of Eastern Saudi Arabia," Br J Haematology, 1978, Vol. 40, pp. 415-429.	
	CFF	PERRINE, Susan P., et al., "Butyric Acid Analogues Augment γ -Globin Gene Expression in Neonatal Erythroid Progenitors," Biochem Biophys Res Comm, 1987, Vol. 148, No. 2, pp. 694-700.	
	CGG	PERRINE, Susan P., et al., "Butyrate Infusions in the Ovine Fetus Delay the Biologic Clock for Globin Gene Switching," Proc. Natl. Acad. Sci. USA, 1988, Vol. 85, pp. 8540-8542.	
	CHH	PERRINE, Susan P., et al., "A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β -Globin Disorders," N Engl J Med, 1993, Vol. 328, No. 2, pp. 81-86.	
	CII	RODGERS, Griffin P., et al., "Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease," N Engl J Med, 1993, Vol. 328, No. 2, pp. 73-80.	
	CJJ	SAFAYA, S., et al., "Augmentation of γ -Globin Gene Promoter Activity by Carboxylic Acids and Components of the Human β -Globin Locus Control Region," Blood, 1994, Vol. 84, No. 11, pp. 3929-3935.	
	CKK	STAMATOYANNOPOULUS, George, et al., "Fetal-Hemoglobin Induction by Acetate, a Product of Butyrate Catabolism," Blood, 1994, Vol. 84, No. 9, pp. 3198-3204.	
	CLL	WEINBERG, R.S., et al., "Low Oxygen Enhances Sickle and Normal Erythropoiesis and Fetal Hemoglobin Synthesis In Vitro," Hemoglobin, 1995, Vol. 19, No. 5, pp. 263-275.	
	CMM	WELFORD, Richard W.D., et al., "The Selectivity and Inhibition of AlkB," J Bio Chem, 2003, Vol. 278, No. 12, pp. 10157-10161.	
	CNN	WOOD, W.G., et al., "Developmental Genetics of the Human Haemoglobins," Biochem J., 1983, Vol. 215, pp. 1-10.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.